CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
LA JOLLA, Calif., Feb. 7, 2024 /PRNewswire/ — CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 10:40am – 11:10am ET.
Related news for (CALC)
- CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
- CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
- CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure
- CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting
- CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates